Jaswinder Singh, MD
Hematology & Oncology · Kansas City, MONPI 1093747677
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.2%. Reporting peaked in 2019 at $17,723 and has fallen 60.2% since, to $7,051 in 2025. Among hematology & oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,043 payments — averaging $44.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$10K
- AstraZeneca$6K
- Bristol Myers Squibb$6K
- Flowonix Medical Incorporated$4K
- Novartis$2K
- Mylan Inc.$2K
- plus $16K from 54 others
Across 442 payments — averaging $8758.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.4M
- Astrazeneca UK Limited$768K
- Amgen$619K
- E.r. Squibb & Sons, L.L.C.$206K
- Incyte Corporation$184K
- Janssen Research & Development, LLC$178K
- plus $562K from 16 others
What the payments were for
- Consulting fees$9,42820%
- Speaking & faculty fees$15,28933%
- Food & beverage$20,81945%
- Education$5341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONFOCUS$9,713
- FOUNDATIONONE CDX$9,713
- FOUNDATIONONE HEME$9,713
- FOUNDATIONONE$9,713
- FOUNDATIONONE LIQUID$9,387
- Abraxane$5,625
- Prometra II$3,597
- IMFINZI$2,800
- FOUNDATIONONE LIQUID CDX$326
- BLENREP$238
- Vascular Lithotripsy$200
- MI CANCER SEEK$161
- OPDIVO$151
- ALIYA SYSTEM$147
- PROVENGE$146
- XGEVA$127
- GENERAL VASCULAR ACCESS$125
- TUKYSA$119
- TAGRISSO$119
- BESREMI$112
How this compares
$46,070 in reported general payments places this provider in the 90th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 49 | $1,044,189 |
| CalquenceAcalabrutinib Maleate | 77 | $996,845 |
| XtandiEnzalutamide | 52 | $755,549 |
| LenvimaLenvatinib Mesylate | 23 | $663,446 |
| Lenalidomide | 39 | $653,542 |
| Abiraterone Acetate | 330 | $541,807 |
| PomalystPomalidomide | 25 | $533,059 |
| LonsurfTrifluridine/Tipiracil Hcl | 40 | $483,972 |
| BrukinsaZanubrutinib | 29 | $443,280 |
| TibsovoIvosidenib | 13 | $431,271 |
| NubeqaDarolutamide | 37 | $407,885 |
| VerzenioAbemaciclib | 19 | $302,587 |
| AlecensaAlectinib Hcl | 14 | $264,731 |
| JakafiRuxolitinib Phosphate | 16 | $246,279 |
| BraftoviEncorafenib | 12 | $205,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $5,911 | $1,044,18949 claims |
| AstraZenecaCalquence | $6,046 | $996,84577 claims |
| Astellas Pharma US IncXtandi | $282 | $755,54952 claims |
| Eisai Inc.Lenvima | $484 | $663,44623 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $172 | $541,807330 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,003 | $533,05925 claims |
| Taiho Oncology, Inc.Lonsurf | $140 | $483,97240 claims |
| BayerNubeqa | $38 | $407,88537 claims |
| Lilly USA, LLCVerzenio | $63 | $302,58719 claims |
| Genentech USA, Inc.Alecensa | $285 | $264,73114 claims |
| Incyte CorporationJakafi | $175 | $246,27916 claims |
| Array Biopharma IncBraftovi | $401 | $205,77012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Kansas City
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Whitney HensingKansas City$62K
- Suman KambhampatiKansas City$31K
- Nicholas ShulerKansas City$18K
- Marc RothKansas City$12K
- Tolga TuncerKansas City$10K
- Karan JosanKansas City$8K
- Maureen SheehanKansas City$8K
- David SchlossmanColumbia$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.